Edith van der Nol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Edith van der Nol has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Sebastian J. Pomplun
Leiden University
8 shared publications - Sean M. McKenna
Leiden University
5 shared publications - J. Miguel Mata
Leiden University
4 shared publications - Gerard J. P. van Westen
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
3 shared publications - Laura H. Heitman
Leiden University
2 shared publications - Martin Šícho
CZ-OPENSCREEN, Department of Informatics and Chemistry, Faculty of Chemical Technology, University of Chemistry and Technology Prague, Technická 5, Prague, Czechia, 16 628
2 shared publications
Latest Publications
- Open Access
PROXINAUT: An Automation Platform for Rapid Hit-to-Degrader Discovery
Massive library-based platforms enable rapid early hit discovery, yet subsequent hit resynthesis and validation remain major bottlenecks in drug discovery. This delay is amplified when optimizing hits, or elaborating structures towards more advanced modalities, such as chemical inducers of proximity (CIPs). Here, we report PROXINAUT, an end-to-end workflow integrating self-encoded library-based hit discovery with an automated parallel solid-phase synthesis platform to streamline hit discovery, validation, optimization, and degrader development. As a demonstration, screening a 176k-member benzimidazole library against BRD4 yielded six hit candidates, which were obtained via parallel automated synthesis and validated as submicromolar binders. The automation workflow empowered a rapid structure activity relationship exploration around the whole scaffold and resulted in a variant with six-fold improved binding affinity. Next, we aimed to automatize the development of bifunctional degraders. Solid phase synthesis typically leaves a C-terminal amide as a synthetic artifact that can compromise druglike properties. We developed a strategy to repurpose this resin-attachment site, converting it into functional degrons featuring either FBXO31-targeting C-terminal amides or cereblon-binding cyclic imides. Operating without human intervention, our automated platform executes up to 16 synthetic steps across multiple parallel structures, enabling true de novo synthesis of full bifunctional scaffolds, where ligand, linker and E3 recruiter variations can all be explored within the same workflow. This resulted in cell-active BRD4 degraders with subnanomolar to nanomolar potency. Overall, we show how library selections can merge with multi-step parallel automation to convert hits directly into validated leads and advanced degrader modalities.
Open AccessPROXINAUT: An Automation Platform for Rapid Hit-to-Degrader Discovery
Massive library-based platforms enable rapid early hit discovery, yet subsequent hit resynthesis and validation remain major bottlenecks in drug discovery. This delay is amplified when optimizing hits, or elaborating structures towards more advanced modalities, such as chemical inducers of proximity (CIPs). Here, we report PROXINAUT, an end-to-end workflow integrating self-encoded library-based hit discovery with an automated parallel solid-phase synthesis platform to streamline hit discovery, validation, optimization, and degrader development. As a demonstration, screening a 176k-member benzimidazole library against BRD4 yielded six hit candidates, which were obtained via parallel automated synthesis and validated as submicromolar binders. The automation workflow empowered a rapid structure activity relationship exploration around the whole scaffold and resulted in a variant with six-fold improved binding affinity. Next, we aimed to automatize the development of bifunctional degraders. Solid phase synthesis typically leaves a C-terminal amide as a synthetic artifact that can compromise druglike properties. We developed a strategy to repurpose this resin-attachment site, converting it into functional degrons featuring either FBXO31-targeting C-terminal amides or cereblon-binding cyclic imides. Operating without human intervention, our automated platform executes up to 16 synthetic steps across multiple parallel structures, enabling true de novo synthesis of full bifunctional scaffolds, where ligand, linker and E3 recruiter variations can all be explored within the same workflow. This resulted in cell-active BRD4 degraders with subnanomolar to nanomolar potency. Overall, we show how library selections can merge with multi-step parallel automation to convert hits directly into validated leads and advanced degrader modalities.
- Open Access
- 10 July 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (28) , 29908-29920
Automated Parallel Synthesis Accelerates Virtual Screening Hit Discovery
Virtual screening (VS) is a powerful approach to exploring a vast chemical space, encompassing libraries of millions to billions of compounds. However, the low hit rates of VS require testing numerous candidates to validate true binders, followed by iterative optimization cycles, which makes experimental validation costly and time-consuming. Here, we report COMBINAUT, an automated parallel synthesis platform that generates diverse chemical scaffolds to accelerate hit validation and refinement. Using a faculty-wide collection of in-house building blocks, the system enables enumeration of over 22.9 million compounds, each designed for parallelized synthesis within 32 h using repurposed solid-phase peptide synthesis equipment. Using this platform, we performed large-scale VS targeting the allosteric pocket of the immuno-oncology target, C-C chemokine receptor 2 (CCR2). Our approach facilitated the rapid synthesis and testing of 100 VS hits spanning diverse molecular architectures. In radioligand binding assays, we successfully validated nine hits with distinct scaffolds, including completely novel CCR2 ligand chemotypes. Iterative hit-to-lead optimization using the automated workflow produced cell-active CCR2 antagonists. This work demonstrates the synergy of automated synthesis and VS, enabling the efficient exploration of chemical space and the rapid discovery of novel ligands.
- 10 July 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (28) , 29908-29920
Open AccessAutomated Parallel Synthesis Accelerates Virtual Screening Hit Discovery
Virtual screening (VS) is a powerful approach to exploring a vast chemical space, encompassing libraries of millions to billions of compounds. However, the low hit rates of VS require testing numerous candidates to validate true binders, followed by iterative optimization cycles, which makes experimental validation costly and time-consuming. Here, we report COMBINAUT, an automated parallel synthesis platform that generates diverse chemical scaffolds to accelerate hit validation and refinement. Using a faculty-wide collection of in-house building blocks, the system enables enumeration of over 22.9 million compounds, each designed for parallelized synthesis within 32 h using repurposed solid-phase peptide synthesis equipment. Using this platform, we performed large-scale VS targeting the allosteric pocket of the immuno-oncology target, C-C chemokine receptor 2 (CCR2). Our approach facilitated the rapid synthesis and testing of 100 VS hits spanning diverse molecular architectures. In radioligand binding assays, we successfully validated nine hits with distinct scaffolds, including completely novel CCR2 ligand chemotypes. Iterative hit-to-lead optimization using the automated workflow produced cell-active CCR2 antagonists. This work demonstrates the synergy of automated synthesis and VS, enabling the efficient exploration of chemical space and the rapid discovery of novel ligands.
- Open Access
- 10 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Massive barcode-free chemical screenings enable the discovery of bioactive macrocycles with passive membrane permeability
Synthetic macrocycles offer exceptional potential as therapeutics. However, most high-throughput discovery platforms rely on genetically encoded libraries of large peptide macrocycles, which typically are not optimized for drug like properties. Fully synthetic libraries offer greater flexibility in accessing broader chemical space. Leveraging recent advances in mass spectrometry based library techniques, here we report CycloSEL (Cyclic Self-Encoded Libraries), an end-to-end workflow, that screens synthetic macrocycle libraries enriched in drug-like ‘beyond rule of five’ features. The workflow relies on affinity selections and hit identification by tandem mass spectrometry, eliminating the need for genetic barcodes. We construct a 16 million-member library and validate the approach against the oncology target carbonic anhydrase IX, achieving robust enrichment and accurate identification of true binders. Applying CycloSEL to the acute myeloid leukemia target WD repeat-containing protein 5 (WDR5) yields a macrocycle with subnamolar affinity, and potent inhibition of the WDR5–Mixed-Lineage Leukemia 1 (MLL1) interaction. Subsequent modifications produce a chameleonic macrocycle with passive membrane permeability, serum stability, and anti-proliferative activity in leukemia cells. Together, these results demonstrate that CycloSEL enables discovery of drug-like macrocycles from fully synthetic libraries for intracellular targets.
- 10 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMassive barcode-free chemical screenings enable the discovery of bioactive macrocycles with passive membrane permeability
Synthetic macrocycles offer exceptional potential as therapeutics. However, most high-throughput discovery platforms rely on genetically encoded libraries of large peptide macrocycles, which typically are not optimized for drug like properties. Fully synthetic libraries offer greater flexibility in accessing broader chemical space. Leveraging recent advances in mass spectrometry based library techniques, here we report CycloSEL (Cyclic Self-Encoded Libraries), an end-to-end workflow, that screens synthetic macrocycle libraries enriched in drug-like ‘beyond rule of five’ features. The workflow relies on affinity selections and hit identification by tandem mass spectrometry, eliminating the need for genetic barcodes. We construct a 16 million-member library and validate the approach against the oncology target carbonic anhydrase IX, achieving robust enrichment and accurate identification of true binders. Applying CycloSEL to the acute myeloid leukemia target WD repeat-containing protein 5 (WDR5) yields a macrocycle with subnamolar affinity, and potent inhibition of the WDR5–Mixed-Lineage Leukemia 1 (MLL1) interaction. Subsequent modifications produce a chameleonic macrocycle with passive membrane permeability, serum stability, and anti-proliferative activity in leukemia cells. Together, these results demonstrate that CycloSEL enables discovery of drug-like macrocycles from fully synthetic libraries for intracellular targets.
- Open Access
- 3 March 2026
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 7 (4) , 630-640
Integration of palladium-catalyzed C–N coupling into self-encoded libraries for accelerated hit discovery
We expanded the self-encoded library (SEL) platform via C–N cross-couplings, testing 170+ building blocks and generating a 25.725-member library. We established automated MS/MS decoding and demonstrated robust hit enrichment in screens against CAIX.
- 3 March 2026
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 7 (4) , 630-640
Open AccessIntegration of palladium-catalyzed C–N coupling into self-encoded libraries for accelerated hit discovery
We expanded the self-encoded library (SEL) platform via C–N cross-couplings, testing 170+ building blocks and generating a 25.725-member library. We established automated MS/MS decoding and demonstrated robust hit enrichment in screens against CAIX.
- Open Access
- 18 February 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Automated Parallel Synthesis Accelerates Virtual Screening Hit Discovery
Virtual screening (VS) is a powerful approach to explore vast chemical space, encompassing libraries of millions to billions of compounds. However, the low hit rates of VS require testing numerous candidates to validate true binders, followed by iterative optimization cycles, making experimental validation costly and time-consuming. Here, we report COMBINAUT, an automated parallel synthesis platform that generates diverse chemical scaffolds to accelerate hit validation and refinement. Using a faculty-wide collection of in-house building blocks, the system enables enumeration of over 22.9 million compounds, each designed for parallelized synthesis within 1-32 hours using repurposed solid-phase peptide synthesis equipment. Using this platform, we performed large-scale virtual screening targeting the allosteric pocket of the immuno-oncology target, C-C chemokine receptor 2 (CCR2). Our approach facilitated the rapid synthesis and testing of 100 virtual screening hits, spanning diverse molecular architectures. In radioligand binding assays, we successfully validated nine hits with distinct scaffolds, including completely novel CCR2 ligand chemotypes. Iterative hit-to-lead optimization using the automated workflow produced cell-active CCR2 antagonists. This work demonstrates the synergy of automated synthesis and VS, enabling efficient exploration of chemical space and rapid discovery of novel ligands.
- 18 February 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAutomated Parallel Synthesis Accelerates Virtual Screening Hit Discovery
Virtual screening (VS) is a powerful approach to explore vast chemical space, encompassing libraries of millions to billions of compounds. However, the low hit rates of VS require testing numerous candidates to validate true binders, followed by iterative optimization cycles, making experimental validation costly and time-consuming. Here, we report COMBINAUT, an automated parallel synthesis platform that generates diverse chemical scaffolds to accelerate hit validation and refinement. Using a faculty-wide collection of in-house building blocks, the system enables enumeration of over 22.9 million compounds, each designed for parallelized synthesis within 1-32 hours using repurposed solid-phase peptide synthesis equipment. Using this platform, we performed large-scale virtual screening targeting the allosteric pocket of the immuno-oncology target, C-C chemokine receptor 2 (CCR2). Our approach facilitated the rapid synthesis and testing of 100 virtual screening hits, spanning diverse molecular architectures. In radioligand binding assays, we successfully validated nine hits with distinct scaffolds, including completely novel CCR2 ligand chemotypes. Iterative hit-to-lead optimization using the automated workflow produced cell-active CCR2 antagonists. This work demonstrates the synergy of automated synthesis and VS, enabling efficient exploration of chemical space and rapid discovery of novel ligands.
- Open Access
- 5 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
CycloSELs – Massive Screening Platform of barcode-free macrocycle libraries enables the identification of cell-penetrating PPI inhibitors
Synthetic macrocycles offer exceptional potential as therapeutics, combining the ability to engage challenging biological targets with favorable drug-like properties. However, most high-throughput discovery platforms rely on genetically encoded libraries of large peptide macrocycles, which typically exhibit poor cell permeability. Here we report CycloSEL (Cyclic Self-Encoded Libraries): a barcode-free, fully synthetic, ultra–high-throughput platform for the discovery of drug-like macrocycles. CycloSEL couples the combinatorial synthesis of massive macrocycle libraries with affinity-based selection and de novo hit identification by tandem mass spectrometry, eliminating the need for genetic barcodes and expanding chemical space. We constructed a 16 million-member macrocycle library enriched in druglike features and validated the approach against the oncology target carbonic anhydrase IX, achieving robust enrichment and accurate identification of true binders. Applying CycloSEL to the acute myeloid leukemia target WDR5 yielded a macrocycle with 8 nM affinity, which we rapidly optimized to a compound that potently disrupts the oncogenic WDR5–MLL interaction (IC₅₀ = 128 nM), displays excellent serum stability, passive membrane permeability and anti-proliferative activity against leukemia cells. Taken together, CycloSEL is a powerful discovery platform for identifying therapeutic leads against challenging intracellular targets.
- 5 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessCycloSELs – Massive Screening Platform of barcode-free macrocycle libraries enables the identification of cell-penetrating PPI inhibitors
Synthetic macrocycles offer exceptional potential as therapeutics, combining the ability to engage challenging biological targets with favorable drug-like properties. However, most high-throughput discovery platforms rely on genetically encoded libraries of large peptide macrocycles, which typically exhibit poor cell permeability. Here we report CycloSEL (Cyclic Self-Encoded Libraries): a barcode-free, fully synthetic, ultra–high-throughput platform for the discovery of drug-like macrocycles. CycloSEL couples the combinatorial synthesis of massive macrocycle libraries with affinity-based selection and de novo hit identification by tandem mass spectrometry, eliminating the need for genetic barcodes and expanding chemical space. We constructed a 16 million-member macrocycle library enriched in druglike features and validated the approach against the oncology target carbonic anhydrase IX, achieving robust enrichment and accurate identification of true binders. Applying CycloSEL to the acute myeloid leukemia target WDR5 yielded a macrocycle with 8 nM affinity, which we rapidly optimized to a compound that potently disrupts the oncogenic WDR5–MLL interaction (IC₅₀ = 128 nM), displays excellent serum stability, passive membrane permeability and anti-proliferative activity against leukemia cells. Taken together, CycloSEL is a powerful discovery platform for identifying therapeutic leads against challenging intracellular targets.
- Open Access
- 26 May 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Barcode-free hit discovery from massive libraries enabled by automated small molecule structure annotation
Affinity-selection platforms are powerful tools in early drug discovery, but current technologies – most notably DNA-encoded libraries (DELs) – are limited by synthesis complexity and incompatibility with nucleic acid-binding targets. We present a barcode-free self-encoded library (SEL) platform that enables direct screening of ~1 million small molecules in a single experiment. SELs combine tandem mass spectrometry with custom software for automated structure annotation, eliminating the need for external tags for the identification of screening hits. We developed efficient, high-diversity synthesis protocols for a broad range of chemical scaffolds and benchmarked the platform in affinity selections against carbonic anhydrase IX, identifying multiple nanomolar binders. We further applied SELs to flap endonuclease 1 (FEN1) – a disease related DNA-processing enzyme inaccessible to DELs – and discovered potent inhibitors. Taken together, screening barcode-free libraries of this scale is unprecedented, enables access to novel target classes, and promises substantial impact on both academic and industrial early drug discovery.
- 26 May 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessBarcode-free hit discovery from massive libraries enabled by automated small molecule structure annotation
Affinity-selection platforms are powerful tools in early drug discovery, but current technologies – most notably DNA-encoded libraries (DELs) – are limited by synthesis complexity and incompatibility with nucleic acid-binding targets. We present a barcode-free self-encoded library (SEL) platform that enables direct screening of ~1 million small molecules in a single experiment. SELs combine tandem mass spectrometry with custom software for automated structure annotation, eliminating the need for external tags for the identification of screening hits. We developed efficient, high-diversity synthesis protocols for a broad range of chemical scaffolds and benchmarked the platform in affinity selections against carbonic anhydrase IX, identifying multiple nanomolar binders. We further applied SELs to flap endonuclease 1 (FEN1) – a disease related DNA-processing enzyme inaccessible to DELs – and discovered potent inhibitors. Taken together, screening barcode-free libraries of this scale is unprecedented, enables access to novel target classes, and promises substantial impact on both academic and industrial early drug discovery.
- Open Access
- 9 August 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (34) , 19129-19139
Advances in Ultrahigh Throughput Hit Discovery with Tandem Mass Spectrometry Encoded Libraries
Discovering new bioactive molecules is crucial for drug development. Finding a hit compound for a new drug target usually requires screening of millions of molecules. Affinity selection based technologies have revolutionized early hit discovery by enabling the rapid screening of libraries with millions or billions of compounds in short timeframes. In this Perspective, we describe recent technology breakthroughs that enable the screening of ultralarge synthetic peptidomimetic libraries with a barcode-free tandem mass spectrometry decoding strategy. A combination of combinatorial synthesis, affinity selection, automated de novo peptide sequencing algorithms, and advances in mass spectrometry instrumentation now enables hit discovery from synthetic libraries with over 100 million members. We provide a perspective on this powerful technology and showcase success stories featuring the discovery of high affinity binders for a number of drug targets including proteins, nucleic acids, and specific cell types. Further, we show the usage of the technology to discover synthetic peptidomimetics with specific functions and reactivity. We predict that affinity selection coupled with tandem mass spectrometry and automated de novo decoding will rapidly evolve further and become a broadly used drug discovery technology.
- 9 August 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (34) , 19129-19139
Open AccessAdvances in Ultrahigh Throughput Hit Discovery with Tandem Mass Spectrometry Encoded Libraries
Discovering new bioactive molecules is crucial for drug development. Finding a hit compound for a new drug target usually requires screening of millions of molecules. Affinity selection based technologies have revolutionized early hit discovery by enabling the rapid screening of libraries with millions or billions of compounds in short timeframes. In this Perspective, we describe recent technology breakthroughs that enable the screening of ultralarge synthetic peptidomimetic libraries with a barcode-free tandem mass spectrometry decoding strategy. A combination of combinatorial synthesis, affinity selection, automated de novo peptide sequencing algorithms, and advances in mass spectrometry instrumentation now enables hit discovery from synthetic libraries with over 100 million members. We provide a perspective on this powerful technology and showcase success stories featuring the discovery of high affinity binders for a number of drug targets including proteins, nucleic acids, and specific cell types. Further, we show the usage of the technology to discover synthetic peptidomimetics with specific functions and reactivity. We predict that affinity selection coupled with tandem mass spectrometry and automated de novo decoding will rapidly evolve further and become a broadly used drug discovery technology.